The role of Extracellular Vesicles in glycolytic and lipid metabolic reprogramming of cancer cells: Consequences for drug resistance

Cytokine Growth Factor Rev. 2023 Oct:73:150-162. doi: 10.1016/j.cytogfr.2023.05.001. Epub 2023 May 14.

Abstract

In order to adapt to a higher proliferative rate and an increased demand for energy sources, cancer cells rewire their metabolic pathways, a process currently recognized as a hallmark of cancer. Even though the metabolism of glucose is perhaps the most discussed metabolic shift in cancer, lipid metabolic alterations have been recently recognized as relevant players in the growth and proliferation of cancer cells. Importantly, some of these metabolic alterations are reported to induce a drug resistant phenotype in cancer cells. The acquisition of drug resistance traits severely hinders cancer treatment, being currently considered one of the major challenges of the oncological field. Evidence suggests that Extracellular Vesicles (EVs), which play a crucial role in intercellular communication, may act as facilitators of tumour progression, survival and drug resistance by modulating several aspects involved in the metabolism of cancer cells. This review aims to gather and discuss relevant data regarding metabolic reprograming in cancer, particularly involving the glycolytic and lipid alterations, focusing on its influence on drug resistance and highlighting the relevance of EVs as intercellular mediators of this process.

Keywords: Cancer; Drug Resistance; Extracellular Vesicles; Intercellular Communication; Metabolic Reprogramming.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Communication
  • Drug Resistance, Neoplasm
  • Extracellular Vesicles* / pathology
  • Humans
  • Lipids / therapeutic use
  • Neoplasms* / metabolism

Substances

  • Lipids